An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
The vaccine is custom-built based on an analysis of a patient's tumors after surgical removal. The vaccines are designed to train the immune system to recognize and attack specific mutations in cancer cells.
There was little difference in response rates among people whose tumors had a lot of mutations - a typical predictor of immunotherapy response - and those whose tumors did not. Merck said the companies are in talks with U.S. regulators about design of a late-stage trial, which is likely needed for approval of the combination regimen.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancerAn experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
Read more »
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancerModerna cancer vaccine with Merck’s Keytruda delays return of deadly skin cancer
Read more »
Merck in late-stage talks to acquire Prometheus Biosciences -WSJMerck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.
Read more »
Merck to buy Prometheus Biosciences for about $11 blnMerck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Read more »
Merck in talks to acquire Prometheus Biosciences: reportMerck is reportedly in talks to buy the San Diego-based Prometheus Biosciences in a promising deal that could be announced as early as Sunday.
Read more »
Merck to buy Prometheus Biosciences for about $11 billionMerck has agreed to acquire Prometheus Biosciences for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Read more »